Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.51 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16023839 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29323337 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12150018 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29998888 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1376688 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL12151850 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29324916 | 0.80 | NT5E (0.51) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL7162751 | 0.80 | SLC28A1 (0.55) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31705067 | 0.79 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710594 | 0.79 | NT5E (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | SLC28A1 144/4885SLC28A2 283/4885SLC29A1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.